Silo Pharma, Inc. (SILO)
Automate Your Wheel Strategy on SILO
With Tiblio's Option Bot, you can configure your own wheel strategy including SILO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SILO
- Rev/Share 0.0161
- Book/Share -0.0909
- PB 0.4968
- Debt/Equity 0.0
- CurrentRatio 4.728
- ROIC 5.5316
- MktCap 3203142.0
- FreeCF/Share -1.0338
- PFCF -0.6909
- PE -0.4311
- Debt/Assets 0.0
- DivYield 0
- ROE -0.8488
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
Study is expected to deliver final device data and documentation needed for planned FDA IND submission Study is expected to deliver final device data and documentation needed for planned FDA IND submission
Read More
Silo Pharma Announces Pricing of $2 Million Public Offering
Published: May 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
SARASOTA, FL, May 15, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the pricing of a public offering of 3,333,338 shares of common stock (or pre-funded warrants in lieu thereof), together with series A-1 warrants (“Series A-1 Warrants”) to purchase up to 3,333,338 shares of common stock and series A-2 warrants (“Series A-2 Warrants”) to purchase up to 3,333,338 shares of common stock at a combined public offering price of $0.60 per share (or pre-funded warrant in lieu thereof) and …
Read More
Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
— Successfully demonstrates strong tolerability, sustained drug release and safety SARASOTA, FL, April 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo,” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced positive results for its preclinical study evaluating SP-26, a novel extended-release ketamine implant which it believes supports SP-26's potential as a safe, well-tolerated, and long-acting treatment for fibromyalgia. All study endpoints were met, including survival, clinical observations, body weight stability, neurological assessments, and histopathological evaluation.
Read More
Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
SARASOTA, FL, April 28, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a patent application with the U.S. Patent and Trademark Office (USPTO) focused on the neurology drug SPC-14, an intranasal compound for the treatment of Alzheimer's disease (AD) exclusively licensed to Silo Pharma from Columbia University.
Read More
Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials SARASOTA, FL, March 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced first dosing in an investigational new drug (IND)-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetics study of its lead asset, SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD). “This IND-enabling safety study and our concurrent GLP-compliant pharmacokinetic and pharmacodynamic study, if successful, will provide the last preclinical data needed to open an IND for SPC-15,” said Eric …
Read More
Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
SARASOTA, FL, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the U.S. Patent and Trademark Office (USPTO) issued an Issue Notification for our previously filed patent application (No. 17/954,864) titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.” The projected patent number is 12,239,614 and the issue date of such patent will be March 4, 2025.
Read More
Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
SPC-15 combination treatment shows enhanced efficacy in combating stress-induced psychiatric disorders SARASOTA, FL, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for its lead asset SPC-15. Silo currently has patents issued and numerous expanded patent applications pending for SPC-15, a technology that was originally licensed through a collaboration with Columbia University.
Read More
Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
No serious side effects or discomfort observed Final safety and absorption data expected in March 2025 SARASOTA, FL, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced a positive update from an ongoing study evaluating the pharmacokinetics, safety and tolerability of its novel SP-26 ketamine extended-release rods when implanted subcutaneously. The SP-26 implant is a novel self-administered, non-opioid therapeutic intended for the treatment of chronic pain and fibromyalgia.
Read More
About Silo Pharma, Inc. (SILO)
- IPO Date 2021-01-08
- Website https://silopharma.com
- Industry Biotechnology
- CEO Mr. Eric Weisblum
- Employees 3